Independent AI index
for professionals

Home / Safety / Perplexity for the pharmaceutical industry

Perplexity AI

How safe is Perplexity for the pharmaceutical industry?

GDPR profileOur summary of what the provider itself publishes about your data: EU hosting possible, no training on your data for business use, and self-hosting available. Caution means a model with a documented issue, such as an investigation by a regulator. How we measure for the pharmaceutical industryUnknown

The maker of Perplexity publishes little about data protection. Ask about this before you put confidential pharmaceutical industry data into it.

Where does Perplexity stand in the pharmaceutical industry?

Shared spot 16 of 25 options for the pharmaceutical industry (professional tools and general assistants) on the GDPR profile. 3 options, like Perplexity, have an unknown profile. Each tile is an option we track for this field; click to check.

Strong5
Good3
Limited7
Unknown3
Caution7

Published safeguards

None of these three found in what the provider publishes; what is there, you can read below. Know more? Report it

Enterprise plans and the Sonar API are not trained on customer data (SOC 2 Type II; API with zero data retention). For consumer accounts, data use for model improvement can be switched off in the settings.

How to use Perplexity safely

  • Use the business variant and sign a data processing agreement (DPA).
  • Do not enter unnecessary personal data into prompts; anonymise where possible.
  • Ask the provider explicitly where data is stored and processed.
  • Keep a professional in the loop: in this sector it concerns health data of trial participants and patients (special category personal data under art.

Stronger or equally strong in the pharmaceutical industry

CradleCradle (Amsterdam, the Netherlands and Zürich, Switzerland)CastorCastor (Amsterdam, Netherlands)BiolevateBiolevate (Paris, France)Aily LabsAily Labs GmbH (Munich, Germany)ClaudeAnthropic

Questions

How safe is Perplexity for the pharmaceutical industry?
The maker of Perplexity publishes little about data protection. Ask about this before you put confidential pharmaceutical industry data into it. The provider publishes little on this, ask about it before business use.
Does Perplexity train on my data?
Enterprise plans and the Sonar API are not trained on customer data (SOC 2 Type II; API with zero data retention). For consumer accounts, data use for model improvement can be switched off in the settings.
What should I look out for with AI in the pharmaceutical industry?
This sector involves health data of trial participants and patients (special category personal data under Article 9 GDPR) and confidential research data. Ask every provider where the data is stored and whether it is used to train models: Castor hosts in the Netherlands (Google Cloud europe-west4) and does not share data or models between customers, Cradle states that source data never goes to third-party AI models, Iris.ai hosts on AWS in Ireland and Germany. Biolevate and Ennov also run in private cloud or on-premises. With Veeva Vault AI and Yseop, texts go to Anthropic models via Amazon Bedrock; check the region and the data processing agreement. If you work in GxP processes, an AI tool must also be validated (EU GMP Annex 11) and a competent employee remains responsible. For AI in medicines development, the EMA has a reflection paper (2024) and is working with the FDA on joint principles.

Source documents

www.perplexity.aiopenrouter.ai

Everything about Perplexity Best AI for the pharmaceutical industry

Summarised by the editorial team from provider documentation · not legal advice

Last checked: 29 October 2026 · How we check

Next stepAll 25 options for pharmaceutical industryProfessional tools and general assistants side by side, on GDPR profile, price and quality.

Every Friday: what changed in AI for the pharmaceutical industry

New models, prices, oversight and tools, with sources and what it means for you. One email a week, unsubscribe with one click.

View a sample

We only use your address for this newsletter. You confirm first by email.